Impacts of dosing frequency of the combination rifampin-streptomycin on its bactericidal and sterilizing activities against Mycobacterium ulcerans in mice

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 7, 2009, Pages 2955-2959

  Ji, Baohong ^a   Chauffour, Aurélie ^a   Aubry, Alexandra ^a   Robert, Jérome ^a   Ibrahim, Murad ^a   Jarlier, Vincent ^a  

^a SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMPICIN; STREPTOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DISINFECTION; DOSAGE SCHEDULE COMPARISON; FEMALE; MOUSE; MYCOBACTERIOSIS; MYCOBACTERIUM ULCERANS; NONHUMAN; PRIORITY JOURNAL; RELAPSE; TREATMENT DURATION;

ANIMALS; ANTI-BACTERIAL AGENTS; BURULI ULCER; DRUG THERAPY, COMBINATION; FEMALE; MICE; MICE, INBRED BALB C; MYCOBACTERIUM ULCERANS; RIFAMPIN; STREPTOMYCIN; TREATMENT OUTCOME;

EID: 67649922932     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00011-09     Document Type: Article

References (14)

1. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America. 2003. Treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167:603-662.
2. Chauty, A., M.-F. Ardant, A. Adeye, H. Euverte, A. Guedenon, C. Johnson, J. Aubry, E. Neuremberger, and J. Grosset. 2007. Promising clinical efficacy of streptomycin-rifampin combination for treatment of Buruli ulcer (Mycobacterium ulcerans disease). Antimicrob. Agents Chemother. 51:4029-4035.
3. Etuaful, S., B. Carbonnelle, J. Grosset, S. Lucas, C. Horsifield, R. Phillips, M. Evans, D. Ofori-Adjei, E. Klustse, J. Owusu-Boateng, G. K. Amedofu, P. Awuah, E. Ampadu, G. Amofah, K. Asiedu, and M. Wansbrough-Jones. 2005. Efficacy of the combination of rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob. Agents Chemother. 49:3182-3186.
4. Guillemin, I., V. Jarlier, and E. Cambau. 1998. Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria. Antimicrob. Agents Chemother. 42:2084-2088.
5. Ji, B., S. Lefrançois, J. Robert, A. Chauffour, C. Truffot, and V. Jarlier. 2006. In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans. Antimicrob. Agents Chemother. 50:1921-1926.
6. Ji, B., A. Chauffour, J. Robert, S. Lefrançois, and V. Jarlier. 2007. Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice. Antimicrob. Agents Chemother. 51:3737-3739.
7. Ji, B., A. Chauffour, J. Robert, and V. Jarlier. 2008. Bactericidal and sterilizing activities of several orally administered combined regimens against Mycobacterium ulcerans in mice. Antimicrob. Agents Chemother. 52:1912-1916.
8. Lefrançois, S., J. Robert, A. Chauffour, B. Ji, and V. Jarlier. 2007. Curing Mycobacterium ulcerans infection in mice with a combination of rifampin-streptomycin or rifampin-amikacin. Antimicrob. Agents Chemother. 51:645-650.
9. Lipin, M. Y., V. N. Stepanshina, I. G. Shemyakin, and T. M. Shinnick. 2007. Association of specific mutations in katG, ropB, rpsL and rrs genes with spoligotypes of multidrug-resistant Mycobacterium tuberculosis isolates in Russia. Clin. Microbiol. Infect. 13:620-626.
10. Sanger, F., S. Nicklen, and A. R. Coulson. 1977. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA 74:5463-5467.
11. Shi, R., J. Zhang, C. Li, Y. Kazumi, and I. Sugawara. 2007. Detection of streptomycin resistance in Mycobacterium tuberculosis clinical isolates from China as determined by denaturing HPLC analysis and DNA sequencing. Microbes Infect. 9:1538-1544.
12. Tracevska, T., I. Jansone, A. Nodieva, O. Marga, G. Skenders, and V. Baumanis. 2004. Characterisation of rpsL, rrs and embB mutations associated with streptomycin and ethambutol resistance in Mycobacterium tuberculosis. Res. Microbiol. 155:830-834.
13. WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. 2003. Guidelines for surveillance of drug resistance in tuberculosis, 2nd ed., p. 55-56. World Health Organization, Geneva, Switzerland.
14. World Health Organization. 2004. Provisional guidance on the role of specific antibiotics in the management of Mycobacterium ulcerans disease (Buruli ulcer). WHO/CDS/CPE/GBUI/2004.10. World Health Organization, Geneva, Switzerland. http://whqlibdoc.who.int/hq/2004/WHO-CDS-CPE-GBUI-2004.10. pdf.